Skip to main navigation
  • Home

  • Development Programs

  • VX15 Immuno-Oncology

  • VX15 Neurology

  • VX18 Neurology

  • VX15 Autoimmune

  • NKT Vaccine

  • NKT Vaccine

  • ActivMAb®

  • Vaccinia Display

  • Capabilities

  • Optimization

  • Target Identification

  • Publications

  • News & Publications

    • News

    • Publications

  • Careers

  • Corporate

    • Management

    • Partners

    • Contact

  • Investors

    Main navigation

    • Investor Overview
    • News Releases
    • Events
    • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
    • Corporate Governance
      • Documents & Charters
      • Management
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Investor Services
      • Information Request
      • IR Contacts
      • E-mail Alerts
  • Events

  • Presentations

  • Home

  • About

  • Corporate Overview

  • Management

  • Partners

  • Pipeline

  • Pepinemab
    Neurology

  • Pepinemab
    Immuno-Oncology

  • Research & Development Programs

  • Clinical Trials

  • Patients

  • Physicians & Researchers

  • News & Publications

    • News

    • Publications

  • Investors

    Main navigation

    • Investor Overview
    • News Releases
    • Events
    • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
    • Corporate Governance
      • Documents & Charters
      • Management
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Investor Services
      • Information Request
      • IR Contacts
      • E-mail Alerts
  • Events

  • Presentations

  • Careers

  • Contact Us

  • ActivMAb ®

    • Vaccinia

    • Antibody Discovery

    • Antigen Virus

    • Protein Optimization

    • Antigen Discovery

    • Antibody Optimization

    • ActivMAb ® Contact

Science in the service of medicine
  • About
    • Corporate Overview
    • Management
    • Partners
  • Pipeline
    • Pepinemab Neurology
    • Pepinemab Immuno-Oncology
    • Research & Development Programs
  • Clinical Trials
    • Patients
    • Physicians & Researchers
  • News & Publications
    • News
    • Publications
  • Investors

    Main navigation

    • Investor Overview
    • News Releases
    • Events
    • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
    • Corporate Governance
      • Documents & Charters
      • Management
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Investor Services
      • Information Request
      • IR Contacts
      • E-mail Alerts
  • Events
  • Presentations
  • Careers
  • Contact Us
  • ActivMAb ®
    • Vaccinia
    • Antibody Discovery
    • Antigen Virus
    • Protein Optimization
    • Antigen Discovery
    • Antibody Optimization
    • Contact Us

Investors

  • Investor Overview
  • News Releases
  • Events
  • Presentations
  • Stock Information
  • Corporate Governance
  • Financial Information
  • Investor Services

Shareholder Tools

  • Print Page
  • RSS Feeds
  • E-mail Alerts
  • IR Contacts
  • LinkedIn
  • Twitter

Filter by content type

  • (-) News (57)

Filter by form group

Filter by year

  • 2022 (7)
  • 2021 (4)
  • 2020 (13)
  • 2019 (19)
  • 2018 (11)
  • 2017 (1)
  • 2016 (2)
News

Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer

November 10, 2022 - … . Vaccinex reported that results of this Phase 1b/2 CLASSICAL-Lung trial showed a 25-33% Overall Response Rate (ORR) for … . Vaccinex reported that results of this Phase 1b/2 CLASSICAL-Lung trial showed a 25-33% Overall Response Rate …
News

Vaccinex Reports Second Quarter 2022 Results and Provides Corporate Update; Excellent Progress in Pepinemab Clinical Programs

August 15, 2022 - … clinical trial costs as a result of the completion of the CLASSICAL-Lung and SIGNAL studies phase 2 trials, partially offset by … clinical trial costs as a result of the completion of the CLASSICAL-Lung and SIGNAL studies phase 2 trials, partially …
News

Vaccinex Reports First Quarter 2022 Results and Provides Corporate Update

May 16, 2022 - … clinical trial costs as a result of the completion of the CLASSICAL-Lung and SIGNAL studies, partially offset by setup expenses … clinical trial costs as a result of the completion of the CLASSICAL-Lung and SIGNAL studies, partially offset by setup …
News

Vaccinex Reports 2021 Financial Results and Provides Corporate Update

March 31, 2022 - … of patients enrolled in clinical trials, especially the CLASSICAL-Lung and SIGNAL studies. General and Administrative Expenses. … . The Company believes that results of this Phase 1b/2 CLASSICAL-Lung trial supports increased benefit of …
News

Vaccinex, Inc. Announces Upcoming Presentation at the 2022 American Association for Cancer Research Meeting Updating the Phase 1b Segment of the KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Meta

March 9, 2022 - … . Vaccinex reported that results of the Phase 1b/2 CLASSICAL-Lung trial showed a 25-33% Overall Response Rate (ORR) for … . Vaccinex reported that results of the Phase 1b/2 CLASSICAL-Lung trial showed a 25-33% Overall Response Rate …
News

Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1b/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer

News

Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Interim Safety Analysis

January 4, 2022 - … . Vaccinex reported that results of the Phase 1b/2 CLASSICAL-Lung trial showed a 25-33% Overall Response Rate (ORR) for … . Vaccinex reported that results of the Phase 1b/2 CLASSICAL-Lung trial showed a 25-33% Overall Response Rate …
News

Vaccinex Reports Second Quarter 2021 Financial Results and Provides Corporate Update

August 16, 2021 - … Vaccinex announced the publication of results from the CLASSICAL-Lung phase 1b/2 clinical trial in non-small cell lung cancer … Vaccinex announced the publication of results from the CLASSICAL-Lung phase 1b/2 clinical trial in non-small cell …
News

Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer in the Peer-Reviewed Journal Clinical Cancer Research

April 21, 2021 - … Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer … Research … Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell …
News

Vaccinex Reports First Quarter 2021 Financial Results and Provides Corporate Update

May 17, 2021 - … head and neck cancer Announced publication of results from CLASSICAL-Lung phase 1b/2 clinical trial in non-small cell lung cancer … Announced the publication of results from the CLASSICAL-Lung phase 1b/2 clinical trial in non-small cell …

Pagination

  • Page 1
  • Next page ››

  • About
  • Pipeline
  • Clinical Trials
  • News
  • Careers
  • Contact
Vaccinex Inc.
1895 Mount Hope Avenue, Rochester, NY 14620
P: 585-271-2700
F: 585-271-2765
info@vaccinex.com
  • © 2023 Vaccinex. All rights reserved
  • |
  • Privacy Policy
  • |
  • Site by Minerva